Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring

Fig. 6

Establishment and verification of early recurrence monitoring models. a Patients who underwent curative-intent surgery in the training cohort and validation cohort were followed up. b Recurrence patterns were compared in patients with HCC (n = 237), iCCA without involving the hepatic hilus (n = 80) and the training and validation cohorts (n = 118) from a single center to determine the best cutoff for early recurrence of CCA-BO patients. c Patients were grouped by their circRNA abundance to compare the recurrence-free survival. d Patients were grouped by the presence of early recurrence (1 year) to compare circRNA abundance. e ROC curves of bile and serum circRNA signatures (Bile-ERS and Serum-ERS) were illustrated. Patients were grouped by their Bile-ERS/Serum-ERS levels to compare the recurrence-free survival in (f) the training cohort and g the validation cohort. *P < 0.05; **P < 0.01; ***P < 0.001; \({{\rm{n}}.{\rm{s}}.\atop }{\rm{not}}\,{\rm{significant}}\); (Mann–Whitney U test for continuous variables, presented as median with range and quartile; Kaplan–Meier analysis for survival data, Log-Rank test for curve comparison)

Back to article page